Trending...
- State-Wide MLS Launches New Single Sign-On Dashboard Powered by Solid Earth
- Colorado Springs City Council and El Paso County Board of County Commissioners seek volunteers for the City/County Drainage Board
- Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
USPTO allows 26 claims for ophthalmic formulations containing quaternary chitosan derivatives, marking a key step toward U.S. patent protection.
DALLAS - ColoradoDesk -- ClearSight Therapeutics Receives U.S. Patent Notice of Allowance for Ophthalmic Formulation Technology for unmet ocular diseases
Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications
DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."
The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.
More on Colorado Desk
"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."
"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."
In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.
More on Colorado Desk
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.
Media Contact
ClearSight Therapeutics
info@clearsighttx.com
972-983-7761
Allowance marks an intellectual property milestone for innovative biopolymeric formulations developed for ocular applications
DALLAS, TX — [Release Date] — ClearSight Therapeutics today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/380,414, titled "Ophthalmic Solution Containing Quaternary Chitosan Derivatives for Treating Ocular Diseases."
The notice, mailed September 29, 2026, allows 26 claims, including composition and method claims. The allowance represents an important step toward securing U.S. patent protection for ClearSight's ophthalmic formulation technology.
More on Colorado Desk
- Colorado Springs: Victim identified from fatal October 24 crash on East Platte Avenue and Space Center Drive
- Colorado Springs: South Academy Boulevard to close Nov. 20-23 between Astrozon Boulevard and Chelton Road
- Colorado Springs: Victim identified from fatal October 24 crash on South Chelton Road
- Colorado Springs: Willwood Tunnel to reopen Nov. 20 with new traffic direction
- Governor Polis Submits Second Presidential Major Disaster Declaration for Southwestern Colorado Flooding
"This allowance marks an important milestone for ClearSight and the science behind our ophthalmic formulations," said Patrick Smale, co-founder and CEO of ClearSight Therapeutics. "Building a strong intellectual property foundation supports our mission to develop innovative, accessible eye care solutions. We're encouraged by this progress as we continue advancing our technology."
"The formulation work focused on preserving the efficacy and key properties of quaternary chitosan in an ophthalmic solution," said co-inventor Nuria Jimenez, PhD, and co-founder & co-inventor Suchismita Acharya, PhD. "We're pleased that the examiner recognized the stability and antiviral activity data presented in the application, and we look forward to building on this scientific foundation to develop our eyedrop product to help people and expand our patent portfolio."
In its statement of reasons for allowance, the examiner cited evidence of acceptable formulation stability, preserved antiviral activity, and unexpectedly higher antiviral activity at 8- and 24-hour time points. These findings relate to evidence presented during patent examination and do not establish clinical efficacy or regulatory approval.
More on Colorado Desk
- KeysCaribbean Introduces Newly Reduced Rates At Village at Hawks Cay Villas for Thanksgiving Getaways
- 2027 DiscoverCOS Calendar celebrates the beauty of Colorado Springs Parks, Trails and Open Spaces
- NANNNA Shines in Stamford: The Men Who Came to Support Their Wives
- Aoolia Offers Free Virtual Try On Glasses for 1,500+ Frames Using Just a Phone Camera
- In Candor, the people waiting on your survey results can watch them arrive live
About ClearSight Therapeutics
ClearSight Therapeutics is a Dallas/Fort Worth-based company founded in 2023 by eye care industry veterans and partners to develop better solutions for common eye conditions. The company is advancing next-generation over-the-counter ophthalmic products designed to address dryness, irritation, and ocular discomfort. For more information, visit clearsighttx.com.
Media Contact
ClearSight Therapeutics
info@clearsighttx.com
972-983-7761
Source: ClearSight Therapeutics, Inc.
0 Comments
Latest on Colorado Desk
- Colorado Springs: Next week's city council work session, regular meeting canceled
- Colorado Springs: Left turns permanently restricted at East Platte Avenue and North Prospect Street starting Nov. 19
- Colorado Springs City Council and El Paso County Board of County Commissioners seek volunteers for the City/County Drainage Board
- Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
- Individual Entrepreneurs Acquire Peak Petroleum Testing Services of Denver, CO
- Governor Polis, CDPHE celebrate Colorado Recycles Week
- Boulder SEO Marketing Announces Complimentary Live Local AI SEO Webinar: The AI-Era Local SEO Playbook
- Colorado Launches Podcast Chronicling Polis Administration's Statewide Work to Achieve Climate Goals
- Boston Industrial Solutions Introduces the New Volta® M100 Pad Printing Machine
- Not a Black Box Launches TalentOS, the First Talent Harness Operating System
- Governor Polis Pardons Four Turkeys in Colorado's Fourth Annual Turkey Pardon, Thanks Colorado Farmers and Ranchers Who Put Food on Thanksgiving Tables Around the State
- Prime Plumbing & Heating Launches Updated Commercial Plumbing Page for Denver Businesses
- A Diwali Celebration with Heritage at South Brunswick Residents & American Properties
- Law Offices of Larry E. Bray, P.A. Wins Fourth District Appeal Clarifying Limits of Florida's Offer of Judgment Statute
- Colorado Springs: Podcast: Matt is history
- Holiday Magic Returns to Downtown Downers Grove November 27-29
- What If the Greatest Gift This Holiday Season Came in a Dream of Your Loved One in Spirit?
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
- LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
- Record Q3 Revenue and Gross Profit Delivered: Revenue Surges 40%, Gross Margin Soars to 36% & Adjusted EBITDA Loss Narrows 64% for Cycurion, Inc $CYCU
